Since ERGIC1 was highly expressed in most primary prostate tumors, and ERGIC1 silencing was able to downregulate ERG expression, it is an intriguing potential drug target especially for the ERG oncogene expressing tumors. The gene discussed is ERG; the disease is prostate neoplasm.